Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. XOMA
stocks logo

XOMA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
11.10M
+27.38%
-0.197
+227.78%
11.80M
-25.84%
-0.150
-350%
11.70M
-10.88%
-0.140
-131.82%
Estimates Revision
The market is revising Downward the revenue expectations for XOMA Royalty Corporation (XOMA) for FY2025, with the revenue forecasts being adjusted by -6.18% over the past three months. During the same period, the stock price has changed by -11.66%.
Revenue Estimates for FY2025
Revise Downward
down Image
-6.18%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+100.92%
In Past 3 Month
Stock Price
Go Down
down Image
-11.66%
In Past 3 Month
Wall Street analysts forecast XOMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XOMA is 69.67 USD with a low forecast of 50.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast XOMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XOMA is 69.67 USD with a low forecast of 50.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 31.130
sliders
Low
50.00
Averages
69.67
High
104.00
Current: 31.130
sliders
Low
50.00
Averages
69.67
High
104.00
Benchmark
Robert Wasserman
Strong Buy
Initiates
$35
2025-04-17
Reason
Benchmark
Robert Wasserman
Price Target
$35
2025-04-17
Initiates
Strong Buy
Reason
Benchmark analyst Robert Wasserman initiated coverage of Xoma with a Buy rating and $35 price target. Xoma has expanded its royalty aggregate business through acquisitions and internal growth over the past several years, notes the analyst, who expects the R&D pipeline and recently completed commercial asset acquisitions to continue to drive double digit revenue growth over the next several years.
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$104
2025-03-28
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$104
2025-03-28
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$104
2025-03-19
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$104
2025-03-19
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Maintains
$123 → $104
2025-02-03
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$123 → $104
2025-02-03
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$123
2025-01-07
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$123
2025-01-07
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$123
2024-12-13
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$123
2024-12-13
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Xoma Royalty Corp (XOMA.O) is -65.30, compared to its 5-year average forward P/E of -19.41. For a more detailed relative valuation and DCF analysis to assess Xoma Royalty Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-19.41
Current PE
-65.30
Overvalued PE
36.24
Undervalued PE
-75.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
23.34
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
106.99
Undervalued EV/EBITDA
-60.32

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
18.57
Current PS
0.00
Overvalued PS
34.17
Undervalued PS
2.96
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

XOMA News & Events

Events Timeline

(ET)
2025-11-26
09:04:43
Mural Oncology Reveals Final Cash Payment Due Upon Acquisition Completion
select
2025-11-21 (ET)
2025-11-21
07:47:25
Xoma Completes Acquisition of Lava Therapeutics
select
2025-11-13 (ET)
2025-11-13
07:41:40
Lava Therapeutics plans to withdraw from Nasdaq listing
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-04Globenewswire
Mural Oncology to be Acquired by XOMA Royalty, Effective December 5, 2025
  • Acquisition Approval: The High Court of Ireland has sanctioned the scheme of arrangement between Mural Oncology and its shareholders, allowing XRA 5 Corp. to acquire all issued shares of Mural, which is expected to enhance liquidity for Mural's shareholders by providing cash compensation effective December 5, 2025.
  • Transaction Timeline: Mural shares are expected to cease trading on Nasdaq on December 4, 2025, with cash compensation distribution to shareholders anticipated to be completed by December 19, ensuring prompt access to funds and boosting shareholder confidence post-transaction.
  • Legal Compliance: The acquisition adheres to Chapter 1 of Part 9 of the Irish Companies Act, ensuring the legality and transparency of the transaction, which mitigates potential legal risks and enhances market trust in Mural's future prospects.
  • Market Reaction Anticipation: As the acquisition progresses, market interest in Mural is expected to rise, potentially attracting more investors to XOMA Royalty's strategic positioning, thereby further strengthening its market position in the biopharmaceutical sector.
[object Object]
Preview
8.5
12-04Newsfilter
Mural Oncology to be Acquired by XOMA Royalty, Effective December 5, 2025
  • Acquisition Scheme Approved: The High Court of Ireland has sanctioned the arrangement scheme between Mural and its shareholders, whereby XRA 5 Corp. will acquire all issued shares of Mural, with the transaction expected to become effective on December 5, 2025, marking a new investment opportunity for Mural's shareholders.
  • Transaction Timeline: Mural shares are expected to cease trading on Nasdaq on December 4, 2025, with the Court Order to be delivered to the Irish Registrar on December 5, ensuring a smooth transaction process that reflects the company's strategic adjustments in the capital markets.
  • Cash Distribution Plan: Under the scheme, XRA 5 Corp. will pay cash consideration to Mural shareholders, with distributions expected to commence shortly after the effective date and all payments to be completed by December 19, 2025, ensuring timely returns for shareholders.
  • Legal Compliance: The acquisition adheres to Irish takeover rules, with Mural's board accepting responsibility for the accuracy of the information, enhancing transparency and compliance, which bolsters investor confidence and maintains the company's reputation.
[object Object]
Preview
8.5
11-26Newsfilter
Mural Oncology Announces $2.035 Cash Per Share in XOMA Royalty Acquisition
  • Transaction Details: Mural Oncology has finalized the additional price per share at $0.000 as per the transaction agreement with XOMA Royalty and its wholly-owned subsidiary, with the acquisition expected to close in early December 2025, marking a significant step in the company's strategic expansion.
  • Cash Compensation: The acquisition will provide Mural shareholders with a cash consideration of $2.035 per share, and despite the additional price being $0.000, it reflects the acquirer's recognition of Mural's future potential, which may enhance market confidence in Mural.
  • Legal Procedures: The acquisition is subject to approval by the Irish High Court, in accordance with Chapter 1 of Part 9 of the Irish Companies Act 2014, demonstrating the company's commitment to strategic restructuring within a compliant legal framework.
  • Market Reaction: Although the acquisition price is low, market reactions to Mural may be influenced by the company's integration capabilities post-acquisition and its future growth potential, prompting investors to monitor subsequent developments to assess long-term value.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Xoma Royalty Corp (XOMA) stock price today?

The current price of XOMA is 31.13 USD — it has increased 0.42 % in the last trading day.

arrow icon

What is Xoma Royalty Corp (XOMA)'s business?

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

arrow icon

What is the price predicton of XOMA Stock?

Wall Street analysts forecast XOMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XOMA is 69.67 USD with a low forecast of 50.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Xoma Royalty Corp (XOMA)'s revenue for the last quarter?

Xoma Royalty Corp revenue for the last quarter amounts to 9.35M USD, increased 29.93 % YoY.

arrow icon

What is Xoma Royalty Corp (XOMA)'s earnings per share (EPS) for the last quarter?

Xoma Royalty Corp. EPS for the last quarter amounts to 0.70 USD, decreased -144.03 % YoY.

arrow icon

What changes have occurred in the market's expectations for Xoma Royalty Corp (XOMA)'s fundamentals?

The market is revising Downward the revenue expectations for XOMA Royalty Corporation (XOMA) for FY2025, with the revenue forecasts being adjusted by -6.18% over the past three months. During the same period, the stock price has changed by -11.66%.
arrow icon

How many employees does Xoma Royalty Corp (XOMA). have?

Xoma Royalty Corp (XOMA) has 13 emplpoyees as of December 05 2025.

arrow icon

What is Xoma Royalty Corp (XOMA) market cap?

Today XOMA has the market capitalization of 383.88M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free